AFAP1 and neoplasm: As shown in Fig. 5a-c, compared with the shRNA-NC group, tumor volume and tumor weight of the shRNA-AFAP1-AS1–1 group significantly decreased (p < 0.05), while increased in the miR-384 inhibitor group (p < 0.05).